SGS Invests in New E&L Laboratory in India
SGS is investing in a new E&L lab in Navi Mumbai, India, that will provide testing services.
SGS announced on Oct. 12, 2021, that it is investing in a new extractables and leachables (E&L) testing laboratory in Navi Mumbai, India. The lab is set to open by the end of 2021 and will provide testing services for verifying product safety for pharmaceutical, biopharmaceutical, and medical device companies in Southeast Asia.
The new lab will be approximately 3000 ft.2 and will offer a broad spectrum of the latest E&L testing solutions, including:
- gas chromatography–mass spectrometry (GC–MS) and headspace–GC/MS for the analysis of semi-volatile and volatile components
- liquid chromatography with tandem mass spectrometry (LC–MSMS) for the quantitative analysis of trace leachable components
- high resolution LC–MSMS to generate data that supports identification of unknown components
- and inductively coupled plasma–MS to quantitate screening and identification of inorganics.
This laboratory in India will complement SGS's existing testing network. The company has three other E&L centers of excellence located in the United States, Germany, and China.
Source: SGS
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
